Trending News

FDA Greenlights Agamree for Duchenne Muscular Dystrophy on October 26, 2023

FDA Greenlights Agamree for Duchenne Muscular Dystrophy on October 26, 2023

What is Agamree prescribed for?   Agamree is prescribed for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. What is Agamree and what does it do? Agamree,  pronounced ah gam' ree, (generic name: vamorolone), is a medication that was approved by the FDA to help treat Duchenne muscular dystrophy (DMD).  DMD...

FDA Approves Bimzelx for Plaque Psoriasis: A New Hope for Patients as of October 17, 2023

FDA Approves Bimzelx for Plaque Psoriasis: A New Hope for Patients as of October 17, 2023

What is Bimzelx prescribed for?  Bimzelx is prescribed to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. What is Bimzelx and what does it do? Bimzelx, pronounced bim zel’ ex, (generic name: bimekizumab-bkzx) is a medication approved by the FDA to help adults with moderate to severe plaque...